CTLA-4-directed Blocking Antibody [EPC] - N0000182635

Pharmacologic Code	N0000182635
Pharmacologic Name	CTLA-4-directed Blocking Antibody
Pharmacologic Uses	cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) blocking antibody human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody
Pharmacologic Concept	Established Pharmacologic Classes - [EPC]
Pharmacologic Concept Description	An established pharmacologic class is a term or phrase that is scientifically valid and clinically meaningful according to the following definitions: A scientifically valid pharmacologic class is supported by documented and submitted empiric evidence showing that the drug's pharmacologic class is known, not theoretical, and relevant and specific to the indication. A clinically meaningful pharmacologic class term or phrase enhances the ability of professionals to understand physiologic effects related to the indication or to anticipate undesirable effects that may be associated with the drug or pharmacologic class.

The table contains 4 products whose active ingredient are classified under the same pharmacologic class CTLA-4-directed Blocking Antibody [EPC].

	NDC	Proprietary Name	Non-Proprietary Name	Dosage Form	Route Name	Company Name	Status
	0003-2327	Yervoy	Non-Proprietary Name: Ipilimumab	Injection	Intravenous	E.r. Squibb & Sons, L.l.c.	ACTIVE
	0003-2328	Yervoy	Non-Proprietary Name: Ipilimumab	Injection	Intravenous	E.r. Squibb & Sons, L.l.c.	ACTIVE
	0310-4505	Imjudo	Non-Proprietary Name: Tremelimumab	Injection, Solution	Intravenous	Astrazeneca Pharmaceuticals Lp	ACTIVE
	0310-4535	Imjudo	Non-Proprietary Name: Tremelimumab	Injection, Solution	Intravenous	Astrazeneca Pharmaceuticals Lp	ACTIVE